Key Points at a Glance
- Weight-loss injections such as Wegovy or Mounjaro can generally be stopped.
- After treatment ends, their effects on hunger, appetite, and fullness gradually wear off.
- Many people regain some of the weight they previously lost.
- Weight regain is not a personal failure and is often influenced by biological factors.
- Whether treatment should continue, change, or stop depends on health, response, and tolerability.
- A medically planned transition and long-term support may help maintain weight loss.
Starting a weight-loss injection does not mean signing up for treatment for life. Wegovy, Mounjaro, and other medications can generally be stopped. However, once treatment ends, their effects on hunger, appetite, and fullness gradually wear off, which is why many people regain weight.
Whether treatment should be continued, adjusted, or stopped depends on your health, treatment response, tolerability, and individual risk of weight regain. This article explains the evidence and what a long-term plan may look like.
The central answer
A weight-loss injection does not automatically have to be used forever
A weight-loss injection does not automatically have to be used forever. For many people, longer-term treatment may still be medically appropriate because reaching a target weight does not eliminate the underlying tendency to regain weight. Whether treatment should be continued, adjusted, or stopped should therefore be decided individually with a physician.
Once You Start a Weight-Loss Injection, Do You Have to Stay on It Forever?
The statement “once you start a weight-loss injection, you have to stay on it forever” is too absolute. It combines two separate questions:
- Can a weight-loss injection generally be stopped?
- Can the weight loss be maintained after treatment ends?
The first question has a clear answer: yes. Medications such as Wegovy and Mounjaro can generally be stopped. Starting treatment does not create an obligation to continue indefinitely.
The second question is more complicated. Studies show that many people regain weight after stopping treatment. However, this does not mean that everyone regains all the weight they lost or that a successful end to treatment is impossible.
A weight-loss injection is not a lifelong contract. At the same time, it is not a short course of treatment after which the biological drivers of obesity automatically disappear. The medically appropriate interpretation lies between these two extremes.
Myth and medical context
Stopping is possible, but it may affect weight maintenance
Treatment is neither a lifelong obligation nor a short-term cure. The individual medical situation is what matters.
Myth
Once you start, you can never stop
A treatment that has been started can generally be stopped or changed.
Medical context
Stopping should be planned
Health, treatment response, related conditions, and the strategy for maintaining weight all need to be considered.
Myth
Everyone immediately regains all the weight
Weight regain is common, but the pace and amount vary considerably.
Medical context
Study averages are not personal predictions
Some people maintain more of their weight loss, while others regain weight more quickly or to a greater extent.
Why Weight-Loss Injections Are Often Used Longer Term
Weight-loss injections such as Wegovy with semaglutide and Mounjaro with tirzepatide are not designed as short-term diet products. They are used for medical weight management in people with obesity or overweight and certain weight-related health conditions.
During treatment, the active ingredients affect signaling pathways involved in hunger, appetite, fullness, and food intake. Many patients report feeling full sooner, needing smaller portions, and thinking about food less intensely.
Treatment can therefore reduce some of the biological resistance to weight loss. However, it does not necessarily eliminate all the factors that contributed to the development or persistence of obesity.
These factors may include:
Why the effect does not simply remain
Several factors can contribute to weight regain
A lower body weight does not automatically change every biological, medical, and everyday factor that existed before treatment.
Hunger and fullness
Genetically and hormonally influenced signals may become more noticeable again after treatment ends.
Biological compensation
After weight loss, the body may conserve energy and strengthen appetite-promoting signals.
Health conditions and medications
Related conditions or other medications may continue to influence weight and metabolism.
Stress and sleep
Chronic stress and inadequate sleep can make hunger, eating patterns, and recovery more difficult to manage.
Daily life and environment
Food availability, time pressure, and opportunities for physical activity do not automatically change with weight loss.
Risk of recurrence
Obesity can be chronic and relapsing. Successful treatment may therefore require long-term support.
Obesity is therefore recognized as a chronic condition that often recurs. Similar to high blood pressure, a treatment does not automatically become unnecessary simply because the measured value improves. A lower body weight may be evidence that treatment is working.
This comparison does not mean that every person needs a weight-loss injection for life. It does explain why reaching a lower weight alone is not an automatic reason to stop treatment immediately.
Individual treatment planning
Do not choose treatment duration by a fixed calendar
Whether a weight-loss injection should be started, continued, adjusted, or stopped depends on your health, treatment response, and tolerability.
What Happens After Stopping a Weight-Loss Injection?
The effect does not disappear within hours of the last injection. These active ingredients are eliminated from the body over a longer period. Their effects on appetite, fullness, and food intake therefore decline gradually.
Several changes may become noticeable over the following weeks:
Typical progression
The medication’s effect gradually decreases
These changes do not occur at the same pace or intensity for everyone.
The active ingredient is eliminated
After the last injection, medication support declines over an extended period.
Hunger may return
Appetite, urges to snack, and thoughts about food may become more frequent or intense.
Fullness may change
Fullness may occur later, and portion sizes may increase without conscious intent.
Weight may increase
If energy intake rises, body weight may gradually increase again.
These changes do not mean that treatment caused dependence. Weight regain is also not proof of insufficient discipline. Rather, part of the medication support is removed while the biological mechanisms that regulate weight remain active.
Why the Body Pushes Back After Weight Loss
The human body often responds to substantial weight loss with adaptations. Energy needs decline, while appetite-promoting signals may increase. From a biological perspective, this compensation helps protect against further weight loss.
This can occur regardless of whether weight was lost with medication, dietary changes, or another treatment. Weight-loss injections can partly counteract this response while they are being used. After treatment stops, that effect is no longer available to the same degree.
Important: Weight regain is not a moral judgment or a personal failure. It may reflect the chronic nature of obesity and the body’s biological response to weight loss.
What Studies Show About Stopping Wegovy and Mounjaro
Randomized studies provide important evidence about what happens when effective medication treatment ends. However, these studies report averages for groups of participants. They cannot precisely predict the weight trajectory of an individual person.
Key withdrawal studies
Weight regain after treatment is common, but not identical for everyone
The results describe average changes in study groups and cannot reliably predict an individual course.
STEP 1 extension
Semaglutide 2.4 mg
One year after stopping, participants had regained about two-thirds of their previous weight loss on average. Their mean weight still remained below baseline.
SURMOUNT-4
Tirzepatide
After switching to placebo, weight increased by an average of 14.0% over 52 weeks. With continued treatment, weight fell by another 5.5% during the same period.
2026 BMJ meta-analysis
37 studies
Across all medications studied, mean weight regain after stopping was 0.4 kg per month. The modeled rate was higher for newer incretin-based medications.
What Did the STEP 1 Extension Study Show About Semaglutide?
In STEP 1, adults with overweight or obesity received semaglutide 2.4 mg or placebo for 68 weeks. After study medication ended, a subgroup was followed for another year.
With semaglutide, mean weight loss had reached 17.3% by week 68. By week 120, participants had regained an average of 11.6 percentage points. Mean weight loss compared with baseline therefore remained 5.6%.
Several cardiometabolic measures that had previously improved moved back toward baseline after treatment ended. The study therefore primarily shows that a substantial part of the treatment effect did not persist after withdrawal.1
What Did SURMOUNT-4 Show About Tirzepatide?
In SURMOUNT-4, all participants first received tirzepatide for 36 weeks. During this open-label lead-in period, body weight decreased by an average of 20.9%.
Participants were then assigned either to continue tirzepatide for another 52 weeks or to switch to placebo. From randomization onward, weight increased by an average of 14.0% in the placebo group. With continued tirzepatide, it decreased by another 5.5%.
From the start of the study through week 88, mean weight loss was 25.3% with continued tirzepatide and 9.9% after switching to placebo.2
What Did the Large 2026 Meta-Analysis Find?
A systematic review published in the BMJ in 2026 analyzed 37 studies of different medications used for weight management.
Across all medications, mean weight regain was 0.4 kilograms per month. The modeled rate was 0.5 kilograms per month for incretin-based medications and 0.8 kilograms per month for newer agents such as semaglutide and tirzepatide. The model suggested a return toward baseline weight after approximately 1.7, 1.6, and 1.5 years, respectively.
These time estimates are model-based and are not certain predictions. Longer follow-up data beyond one year were particularly limited for newer incretin-based medications. Cardiometabolic improvements also moved partly back toward baseline after treatment ended.3
Does Everyone Regain Weight After Stopping?
No. Studies show a clear tendency toward weight regain, but not the same course for every person.
Some people regain weight relatively quickly. Others maintain a substantial portion of their weight loss for longer. Some may even continue to lose weight initially. Differences may depend on several factors:
Why outcomes differ
Six factors influence weight maintenance
Studies report group averages. Individual outcomes depend on several medical and personal factors.
Treatment duration
How long the body was supported by treatment.
Amount of weight lost
How much weight was lost and how quickly it occurred.
Return of appetite
How strongly hunger, food thoughts, and fullness change.
Medical situation
Which related conditions, medications, and metabolic factors are present.
Established routines
Which nutrition, activity, and everyday structures are sustainable.
Ongoing support
Whether medical follow-up or another form of treatment continues.
Why Real-World Data May Look Different
A retrospective study published in 2026 analyzed 7,938 people who stopped injectable semaglutide or tirzepatide in routine clinical practice after three to twelve months of treatment.
Within the following year, 19.6% restarted the original medication. Another 35.2% received a different obesity treatment, including another medication, lifestyle support, or, in a small number of cases, bariatric surgery. In the group treated for obesity, mean weight change from discontinuation to one year later was an increase of 0.5%.
The relatively small mean regain should therefore not be interpreted as proof that weight generally remains stable after stopping without further support. The study instead shows highly variable treatment courses and frequent treatment changes or restarts.4
Interpreting studies correctly
Group averages are not individual predictions
If a study group regains weight on average, that does not mean every participant follows the same course. Conversely, individual success stories cannot show that stopping works smoothly for everyone.
Target Weight Reached: Does Treatment End There?
Reaching a target weight is an important treatment success. However, it does not automatically mark the end of treatment. A new phase often begins: long-term weight maintenance.
During weight loss, the focus is on controlled reduction. Afterward, the treatment goal changes. The priority is no longer continued weight loss, but stabilizing the achieved weight, protecting body composition, and maintaining health improvements.
Several strategies may be considered during this maintenance phase:
Continue treatment
If treatment is effective and well tolerated, it may be continued to support weight stability.
Adjust treatment
Depending on the course, a physician-guided adjustment of the long-term strategy may be appropriate.
Switch treatment
Another suitable treatment may be considered if benefits, tolerability, or life circumstances change.
Stop medication
Stopping should include follow-up, monitoring, and a plan for possible weight regain.
The appropriate option cannot be determined from body weight alone. Blood pressure, blood sugar, blood lipids, waist circumference, muscle mass, hunger, well-being, and related health conditions may also matter.
Practical strategies for the period after medication treatment are available in our article on maintaining weight after weight-loss injections.
How Long Should You Take Wegovy or Mounjaro?
There is no single number of months that applies to every patient. Treatment should be reviewed regularly to determine:
- whether it continues to support the individually agreed treatment goal,
- whether health risk factors are improving,
- whether the medication is well tolerated,
- whether the achieved weight remains stable,
- whether benefits and burdens remain appropriately balanced.
If treatment is effective and well tolerated, longer-term continuation may be appropriate. The World Health Organization specifically identifies GLP-1-based medications as a possible long-term treatment for adults with obesity. However, the recommendation is conditional, partly because data on long-term safety, maintenance, and discontinuation remain limited.56
“Long term” does not automatically mean “forever.” Treatment should be reviewed regularly and may change over time. New medical conditions, side effects, personal preferences, pregnancy planning, changed life circumstances, or new medical evidence may require an adjustment.
Treatment duration
The right duration matters more than the shortest duration
Treatment is not automatically better because it is stopped as quickly as possible. Continuing indefinitely is also not right for everyone. The key is the strategy that best balances benefit, safety, and quality of life over time.
When May Stopping a Weight-Loss Injection Be Appropriate or Necessary?
Treatment may be stopped or changed for a variety of reasons:
Possible reasons
Ending treatment can have medical or personal reasons
Stopping is not automatically a failure. Benefits, risks, and alternatives should be reassessed together.
Insufficient response
The agreed treatment goal is not adequately supported despite an appropriate treatment period.
Side effects
Symptoms persist or create a medically relevant burden.
New contraindications
A changed medical situation requires a new benefit-risk assessment.
Pregnancy planning
Pregnancy or plans to become pregnant require early medical coordination.
Another treatment option
An alternative treatment may be medically more appropriate or better tolerated.
Personal circumstances
Preferences, availability, or financial burden may influence the decision.
Reaching a preferred weight may also be a reason to discuss the next strategy. However, it is rarely the only relevant factor.
Medical guidance is particularly important when semaglutide or tirzepatide is being used not only for weight management but also to treat type 2 diabetes. Stopping may affect blood sugar control and require changes to other medications.
Do Not Pause Treatment on Your Own to Eat More
A weight-loss injection should not be stopped briefly for a vacation, a large meal, or an individual special occasion. Such a pause offers no predictable benefit and may disrupt the treatment schedule and affect tolerability when treatment is restarted.
Extending injection intervals independently or using nonstandard partial doses is also not a reliable maintenance strategy. More information is available in our article on dose reduction and extended injection intervals for weight-loss injections.
Taper a Weight-Loss Injection or Stop It Directly?
There is currently no uniform, sufficiently evidence-based standard tapering schedule for Wegovy, Mounjaro, or other GLP-1-based weight-loss medications. 1278
In major withdrawal studies, active treatment was stopped and replaced with placebo. These studies show that weight regain after stopping is common, but they do not answer whether gradually reducing the dose improves long-term weight maintenance.
Early observational data and practical experience with gradual dose reduction exist, but they do not yet support a general recommendation. Several questions remain unresolved:
Current evidence
There is no broadly established standard tapering schedule
Gradual dose reduction may sound plausible, but it has not been studied well enough to support a general recommendation.
What is already known
- Weight regain is common after treatment stops.
- Major studies did not use a standardized tapering schedule.
- Dose and injection intervals should not be changed independently.
What remains unclear
- Who may benefit from tapering.
- How long dose reduction should take.
- Whether gradual reduction improves weight maintenance.
Neither the dose nor the injection interval should therefore be changed without medical guidance. This also applies after the target weight has been reached.
No independent dosing experiments
A discontinuation plan must fit the medication and medical situation
The decision should be based on approved doses, the specific medication, previous tolerability, and the individual treatment goal.
Continue, Adjust, or Stop: How Is the Decision Made?
The next phase of treatment should ideally be discussed before the target weight is reached. This helps prevent treatment from ending abruptly without follow-up.
The decision may include the following factors:
Individual decision
Continue, adjust, or stop: these points should be reviewed together
Current body weight is not the only consideration. Health, tolerability, daily life, and long-term stability also matter.
Weight trajectory
How much weight was lost, and how stable has the course been?
Health
How have blood pressure, blood sugar, blood lipids, and related conditions changed?
Hunger and fullness
How strongly was appetite regulation affected before treatment?
Tolerability
Are there side effects or other medical burdens?
Daily routines
Which nutrition, activity, and behavioral routines have been established?
Personal situation
What preferences, life circumstances, and long-term goals are involved?
A Plan for the Period After Stopping
If treatment is stopped, the follow-up plan should be defined beforehand. This may include regular medical appointments, nutrition counseling, and monitoring of relevant health measures.
It is also useful to agree on when to seek medical advice again. A gain of one kilogram does not mean treatment has failed. However, a sustained upward trend, substantially increased hunger, or worsening health measures should be discussed early.
The response is not automatically to restart the same maximum dose immediately. Depending on the situation, renewed diagnostic assessment, another treatment, a structured maintenance phase, or gradual dose escalation may be needed.
After reaching target weight
How should treatment continue over the long term?
Have a physician assess whether continuing, adjusting, or stopping treatment is appropriate for your current situation.
What You Can Build During Treatment for the Future
A weight-loss injection should not be viewed in isolation. The period of reduced hunger creates an opportunity to establish structures that may remain helpful if medication is later adjusted or stopped.
These may include:
Preparing for maintenance
Use the period of reduced hunger intentionally
Sustainable routines can support future weight maintenance, but they do not automatically replace the biological effect of treatment.
Meal structure
Regular, balanced meals instead of short-term restrictive rules.
Protein and nutrients
Adequate nutrition despite smaller portions and reduced appetite.
Protect muscle mass
Physical activity and strength training suited to individual capacity.
Understand hunger
Better distinguish early fullness, enjoyment, and true physical hunger.
Stress strategies
Develop alternatives for emotional eating and difficult everyday situations.
Monitor progress
Review health measures and weight trends regularly rather than waiting for substantial regain.
These measures can support weight maintenance, but they cannot guarantee that no regain will occur after stopping. Biological appetite pressure may increase substantially even when routines are followed consistently.
Restarting medication support is therefore not automatically a setback. With a chronic condition, it may be normal to adjust, restart, or continue treatment over the long term.
Conclusion: Do You Have to Take a Weight-Loss Injection Forever?
No. Starting a weight-loss injection does not automatically create a lifelong obligation. Stopping is generally possible.
At the same time, clinical studies show that many people regain weight after ending treatment with semaglutide, tirzepatide, or other medications. This is not simply due to a lack of discipline. A medication effect that previously influenced hunger, fullness, and energy intake is removed. In addition, the body often defends the previous higher weight.
Long-term or ongoing treatment may therefore be appropriate for some patients. Others may stop medication with structured support or switch to another form of treatment.
The most useful question is therefore not “Do I have to take the injection forever?” but “What long-term treatment do I need to keep my weight and health as stable as possible?”
Generally possible
Stopping is not taboo
A treatment that has been started does not automatically have to continue unchanged for life.
Common reality
Weight regain is likely
When the medication effect ends, hunger and biological appetite pressure may return.
What matters
A long-term strategy
Continuing, adjusting, switching, or stopping should be planned and monitored individually.
You can find an overview of medications and treatment options on our pages about weight loss with injections, Wegovy and Mounjaro. A transparent overview of program duration and costs is available on our programs and pricespage.
Free initial consultation
Plan medical weight loss for the long term
During the free initial consultation, we review your starting situation and discuss which treatment approach may generally be suitable for you.
Medical note: This article is for general information and does not replace individualized medical advice. Do not stop prescription treatment or change the dose or injection interval without consulting your treating medical team.
Frequently Asked Questions About Stopping Weight-Loss Injections
Do weight-loss injections have to be taken for life?
Not automatically. Longer-term treatment may be medically appropriate for some patients because obesity is a chronic condition with a risk of recurrence. Others may stop treatment with medical support or switch to another strategy.
What happens when you stop Wegovy?
After Wegovy is stopped, semaglutide’s effects on hunger, appetite, and fullness gradually decline. Food intake may therefore increase again. In the STEP 1 extension, participants regained about two-thirds of their previous weight loss on average within one year.
What happens after stopping Mounjaro?
Hunger may also increase and weight may rise after tirzepatide is stopped. In SURMOUNT-4, switching from tirzepatide to placebo resulted in substantial weight regain over the following year.
Does everyone regain all the weight after stopping?
No. Weight regain is common, but the amount varies considerably. Some people maintain a large portion of their weight loss, while others regain weight more quickly or to a greater degree. Study findings describe averages, not certain personal predictions.
Can you stop a weight-loss injection immediately?
Treatment should not be stopped independently. There is no single tapering schedule that applies to everyone. Whether treatment is stopped directly, adjusted, or gradually reduced should be decided medically based on the medication, health situation, and treatment goal.
Does gradual tapering prevent weight regain?
There is not yet enough reliable evidence to support that conclusion. Early observations of gradual dose reduction exist, but they do not support a general recommendation. Dose and injection intervals should not be changed independently.
Should the injection be stopped as soon as target weight is reached?
Not necessarily. The maintenance phase begins after weight loss. Whether treatment is continued, adjusted, or stopped depends on health, risk of recurrence, tolerability, and personal goals.
Can treatment be restarted after weight regain?
Restarting treatment may be an option, but it requires medical assessment. After a longer interruption, do not restart at the most recent dose on your own. Depending on the medication and length of the interruption, gradual dose escalation may be required again.
Sources
- Wilding JPH et al.: Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Follow-up study examining weight and cardiometabolic changes one year after stopping semaglutide 2.4 mg.
- Aronne LJ et al.: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. Randomized SURMOUNT-4 trial comparing continued tirzepatide treatment with a switch to placebo.
- West S et al.: Weight regain after cessation of medication for weight management. 2026 systematic review and meta-analysis of weight regain and cardiometabolic changes after stopping different weight-management medications.
- Gasoyan H et al.: Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Retrospective real-world study of 7,938 patients examining treatment changes and weight trajectories after discontinuation.
- World Health Organization: Guideline on the use of GLP-1 medicines in treating obesity. Conditional recommendation on the long-term use of liraglutide, semaglutide, and tirzepatide in adults with obesity.
- AWMF: S3 Guideline on the Prevention and Treatment of Obesity. German guideline covering diagnosis, long-term weight management, and medication treatment options.
- European Medicines Agency: Wegovy. Current European product information, indication, and approved use of semaglutide for weight management.
- European Medicines Agency: Mounjaro. Current European product information, indication, and approved use of tirzepatide for weight management and type 2 diabetes.